(Q39198527)

9 September 2017

8 references

19 June 2019

7 August 2019

28 September 2019

2 October 2019

4 November 2019

21 December 2019

1 May 2021

14 July 2021

Metal-Based PSMA Radioligands (English)

1 reference

Kallikrein related peptidase 3

9 September 2017

1 reference

7 August 2019

1 reference

28 September 2019

1 reference

2 October 2019

1 reference

4 November 2019

seminal plasma proteins

1 reference

21 December 2019

1 reference

1 May 2021

1 reference

14 July 2021

Eleni Gourni

1

1 reference

PubMed ID

28338640

9 September 2017

Gjermund Henriksen

series ordinal

2

1 reference

PubMed ID

28338640

9 September 2017

language of work or name

English

0 references

publication date

24 March 2017

9 references

9 September 2017

19 June 2019

7 August 2019

28 September 2019

2 October 2019

4 November 2019

21 December 2019

1 May 2021

14 July 2021

9 references

9 September 2017

19 June 2019

7 August 2019

28 September 2019

2 October 2019

4 November 2019

21 December 2019

1 May 2021

14 July 2021

22

1 reference

9 September 2017

4

1 reference

Creative Commons Attribution

9 September 2017

8 references

19 June 2019

7 August 2019

28 September 2019

2 October 2019

4 November 2019

21 December 2019

1 May 2021

14 July 2021

0 references

Imaging prostate cancer: a multidisciplinary perspective

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Radionuclide and hybrid imaging of recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Radiopharmaceutical development of radiolabelled peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Molecular imaging targeting peptide receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Prostate-specific membrane antigen expression as a predictor of prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Structural and biochemical characterization of the folyl-poly-γ-l-glutamate hydrolyzing activity of human glutamate carboxypeptidase II

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Receptor-mediated endocytosis: the intracellular journey of transferrin and its receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

NAAG peptidase inhibitors and their potential for diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate-specific membrane antigen in staging of clinically localized prostatic carcinoma: comparison with clinical, surgical and histological staging.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Targeting Metastatic Prostate Cancer With Radiolabeled Monoclonal Antibody J591 to the Extracellular Domain of Prostate Specific Membrane Antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Design and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-adherent PSMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Arming antibodies: prospects and challenges for immunoconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Efficient tumor targeting by single-domain antibody fragments of camels

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Aptamers as therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Targeting cancer cells with nucleic acid aptamers.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Oligonucleotide aptamers: new tools for targeted cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

A theranostic "SMART" aptamer for targeted therapy of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper-64 for targeted molecular imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Synthesis and Biological Evaluation of Thiol-Based Inhibitors of Glutamate Carboxypeptidase II: Discovery of an Orally Active GCP II Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Substrate specificity of prostate-specific membrane antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase)

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Production of multimeric prostate-specific membrane antigen small-molecule radiotracers using a solid-phase 99mTc preloading strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

New cross-bridged cyclam derivative CB-TE1K1P, an improved bifunctional chelator for copper radionuclides

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure–activity relationship studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Triazole Appending Agent (TAAG): A New Synthon for Preparing Iodine-Based Molecular Imaging and Radiotherapy Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Preparation and evaluation of carborane-derived inhibitors of prostate specific membrane antigen (PSMA).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Radiofluorination of PSMA-HBED via Al(18)F(2+) Chelation and Biological Evaluations In Vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Synthesis and evaluation of constrained phosphoramidate inhibitors of prostate-specific membrane antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Development of (99m)Tc-labeled asymmetric urea derivatives that target prostate-specific membrane antigen for single-photon emission computed tomography imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

The renaissance of the ⁶⁸Ge/⁶⁸Ga radionuclide generator initiates new developments in ⁶⁸Ga radiopharmaceutical chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

(68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

PSMA PET/CT with Glu-urea-Lys-(Ahx)-[⁶⁸Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Metastatic Prostate Carcinoma Presenting as a Superscan on 68Ga-PSMA PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

68Ga-Labeled Anti-Prostate-Specific Membrane Antigen Peptide as Marker for Androgen Deprivation Therapy Response in Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

The Role of Positron Emission Tomography With (68)Gallium (Ga)-Labeled Prostate-specific Membrane Antigen (PSMA) in the Management of Patients With Organ-confined and Locally Advanced Prostate Cancer Prior to Radical Treatment and After Radical Pros

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

68Ga-PSMA PET/CT Imaging and 153Sm-EDTMP Bone Pain Palliation Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

(68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Widespread Metastatic Prostate Carcinoma Shown by 68Ga-PSMA PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

(R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

⁶⁴Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr immunoconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Radionuclide imaging in drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

[(111)In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

68Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

(64)Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human Studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES22040523

Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.

21 January 2018

1 reference

12 December 2020

Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen

1 reference

12 December 2020

In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer

1 reference

12 December 2020

Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase

1 reference

12 December 2020

In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen

1 reference

12 December 2020

Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium

1 reference

12 December 2020

Prostate-specific membrane antigen expression in normal and malignant human tissues

1 reference

12 December 2020

Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?

1 reference

12 December 2020

Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature

1 reference

12 December 2020

Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.

1 reference

12 December 2020

Early detection of prostate cancer relapse by biochemistry and diagnostic imaging

1 reference

12 December 2020

Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma

1 reference

12 December 2020

Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor

1 reference

12 December 2020

Radiosynthesis of a new PSMA targeting ligand ([18F]FPy-DUPA-Pep)

1 reference

12 December 2020

111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group

1 reference

12 December 2020

ProstaScint(R) Scan: Contemporary Use in Clinical Practice

1 reference

12 December 2020

Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy

1 reference

12 December 2020

Monoclonal antibody-based therapy of a human tumor xenograft with a 177lutetium-labeled immunoconjugate

1 reference

12 December 2020

Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy

1 reference

12 December 2020

The utility of monoclonal antibodies in the imaging of prostate cancer

1 reference

12 December 2020

(68)Ga-labeled peptides in tumor imaging.

1 reference

12 December 2020

Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers

1 reference

12 December 2020

Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer

1 reference

12 December 2020

Radiolabelled aptamers for tumour imaging and therapy.

1 reference

12 December 2020

Overview of prostate-specific membrane antigen

1 reference

12 December 2020

D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake

1 reference

12 December 2020

Synthesis and positron emission tomography evaluation of 18F-Glu-Urea-Lys, a prostate-specific membrane antigen-based imaging agent for prostate cancer

1 reference

12 December 2020

10.3390/MOLECULES22040523

Identifiers

DOI

1 reference

9 September 2017

0 references

1 reference

PubMed ID

28338640